Hope for a rare disease: Eculizumab in neuromyelitis optica

The Lancet Neurology

Volumn 12, Issue 6, 2013, Pages 529-531

  Paul, Friedemann ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

AQUAPORIN 4; AZATHIOPRINE; BETA INTERFERON; CORTICOSTEROID; ECULIZUMAB; FINGOLIMOD; IMMUNOGLOBULIN G ANTIBODY; MITOXANTRONE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; NATALIZUMAB; RITUXIMAB;

BRAIN DAMAGE; CLINICAL FEATURE; DISABILITY; DISEASE SEVERITY; DRUG EFFICACY; DRUG SAFETY; HEMOLYTIC UREMIC SYNDROME; HICCUP; HUMAN; LETTER; LONG TERM CARE; MULTIPLE SCLEROSIS; MYELOOPTIC NEUROPATHY; NEUROENDOCRINE DISEASE; NUCLEAR MAGNETIC RESONANCE IMAGING; PAROXYSMAL NOCTURNAL HEMOGLOBINURIA; PRIORITY JOURNAL; RELAPSE; SPINAL CORD LESION; VOMITING;

ANTIBODIES, MONOCLONAL, HUMANIZED; AQUAPORIN 4; FEMALE; HUMANS; IMMUNOGLOBULIN G; MALE; NEUROMYELITIS OPTICA;

EID: 84877879337     PISSN: 14744422     EISSN: 14744465     Source Type: Journal    
DOI: 10.1016/S1474-4422(13)70089-9     Document Type: Letter

References (17)

1. Wingerchuk DM, Lennon VA, Lucchinetti CF, Pittock SJ, Weinshenker BG The spectrum of neuromyelitis optica. Lancet Neurol 2007, 6:805-815.
2. Lennon VA, Kryzer TJ, Pittock SJ, Verkman AS, Hinson SR IgG marker of optic-spinal multiple sclerosis binds to the aquaporin-4 water channel. J Exp Med 2005, 202:473-477.
3. Jarius S, Ruprecht K, Wildemann B, et al. Contrasting disease patterns in seropositive and seronegative neuromyelitis optica: a multicentre study of 175 patients. J Neuroinflammation 2012, 9:14.
4. Jarius S, Paul F, Franciotta D, et al. Cerebrospinal fluid findings in aquaporin-4 antibody positive neuromyelitis optica: results from 211 lumbar punctures. J Neurol Sci 2011, 306:82-90.
5. Kim W, Kim SH, Huh SY, Kim HJ Brain abnormalities in neuromyelitis optica spectrum disorder. Mult Scler Int 2012, 2012:735486.
6. Popescu BF, Lennon VA, Parisi JE, et al. Neuromyelitis optica unique area postrema lesions: nausea, vomiting, and pathogenic implications. Neurology 2011, 76:1229-1237.
7. Qian P, Lancia S, Alvarez E, Klawiter EC, Cross AH, Naismith RT Association of neuromyelitis optica with severe and intractable pain. Arch Neurol 2012, 69:1482-1487.
8. Jarius S, Wildemann B AQP4 antibodies in neuromyelitis optica: diagnostic and pathogenetic relevance. Nat Rev Neurol 2010, 6:383-392.
9. Kim SH, Kim W, Li XF, Jung IJ, Kim HJ Does interferon beta treatment exacerbate neuromyelitis optica spectrum disorder?. Mult Scler 2012, 18:1480-1483.
10. Kleiter I, Hellwig K, Berthele A, et al. Failure of natalizumab to prevent relapses in neuromyelitis optica. Arch Neurol 2012, 69:239-245.
11. Min JH, Kim BJ, Lee KH Development of extensive brain lesions following fingolimod (FTY720) treatment in a patient with neuromyelitis optica spectrum disorder. Mult Scler 2012, 18:113-115.
12. Kimbrough DJ, Fujihara K, Jacob A, et al. Treatment of neuromyelitis optica: review and recommendations. Mult Scler Relat Disord 2012, 1:180-187.
13. Pittock SJ, Lennon VA, McKeon A, et al. Eculizumab in AQP4-IgG-positive relapsing neuromyelitis optica spectrum disorders: an open-label pilot study. Lancet Neurol 2013, published online April 26. http://dx.doi.org/10.1016/S1474-4422(13)70076-0.
14. Hinson SR, Pittock SJ, Lucchinetti CF, et al. Pathogenic potential of IgG binding to water channel extracellular domain in neuromyelitis optica. Neurology 2007, 69:2221-2231.
15. Saadoun S, Waters P, Bell PA, Vincent A, Verkman AS, Papadopoulos MC Intracerebral injection of neuromyelitis optica immunoglobulin G and human complement produces neuromyelitis optica lesions in mice. Brain 2010, 133:349-361.
16. Rother RP, Rollins SA, Mojcik CF, Brodsky RA, Bell L Discovery and development of the complement inhibitor eculizumab for the treatment of paroxysmal nocturnal hemoglobinuria. Nat Biotechnol 2007, 25:1256-1264.
17. Kurtzke JF Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology 1983, 33:1444-1452.